

Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances

Cambridge University Press & Assessment

978-1-009-18213-3 — Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances

Dima Abdulrahim , Owen Bowden-Jones

Frontmatter

[More Information](#)

Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances

NEPTUNE Clinical Guidance

Dima Abdulrahim

Programme Manager and Principal Researcher for the NEPTUNE Project, Central and North West London NHS Foundation Trust

Owen Bowden-Jones

Consultant Addiction Psychiatrist, Central and North West London NHS Foundation Trust

CAMBRIDGE UNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom
One Liberty Plaza, 20th Floor, New York, NY 10006, USA
477 Williamstown Road, Port Melbourne, VIC 3207, Australia
314–321, 3rd Floor, Plot 3, Splendor Forum, Jasola District Centre,
New Delhi – 110025, India
103 Penang Road, #05–06/07, Visioncrest Commercial, Singapore 238467

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning, and research at the highest international levels of excellence.

www.cambridge.org
Information on this title: www.cambridge.org/9781009182133
DOI: 10.1017/9781009182126

© The Royal College of Psychiatrists 2022

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2022

A catalogue record for this publication is available from the British Library.

ISBN 978-1-009-18213-3 Paperback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

.....
Every effort has been made in preparing this book to provide accurate and up-to-date information that is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors, and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors, and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

Contents

Acknowledgements vi

Part I Introduction and Background

- 1 **An Introduction to Club Drugs and Novel Psychoactive Substances** 1
- 2 **Psychosocial Interventions for Club Drugs and Novel Psychoactive Substances** 22

Part II Drugs with Primarily Depressant Effects

- 3 **Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL)** 37
- 4 **New Benzodiazepine Novel Psychoactive Substances** 65
- 5 **Synthetic Opioid Novel Psychoactive Substances (Fentanyl and Non-fentanyl)** 78
- 6 **Ketamine and Other Novel Psychoactive Substances with Dissociative Effects** 101
- 7 **Nitrous Oxide (N₂O)** 131

Part III Drugs with Primarily Stimulant Effects

- 8A **Introduction to Stimulant Club Drugs and Novel Psychoactive Substances** 143

-
- 8B **Amphetamine-type Stimulants: An Overview** 146
 - 9 **'Ecstasy': MDMA (3,4-Methylenedioxy-N-Methylamphetamine), MDMA Analogues and Drugs with Similar Effects** 165
 - 10 **Methamphetamine** 202
 - 11 **Synthetic Cathinones** 240

Part IV Drugs with Primarily Hallucinogenic Effects

- 12 **Hallucinogenic Drugs** 267

Part V Synthetic Cannabinoid Receptor Agonists

- 13 **Synthetic Cannabinoid Receptor Agonists** 299

Part VI Concluding Remarks

- 14 **Conclusion** 329

Index 330

Acknowledgements

The authors would like to express their gratitude to the EU Action Against Drugs and Organised Crime (EU-ACT) (a project funded by the European Union and implemented by FIIAPP International and Ibero-American Foundation for Administration and Public Policy) for an unrestricted quality improvement grant used to produce this publication.



The authors would like to thank the Health Foundation for supporting the development of the NEPTUNE work through unrestricted educational grants.

The authors would also like to thank the multi-disciplinary groups of experts and experts by experience for their invaluable support in the development of work. The authors would like to extend particular thanks to Paul Dargan, David Wood, Jonathan Dewhurst, Sarah Finley, Fabrizio Schifano, Christopher Whitely, and Luke Mitcheson.